Skip to main content
SpringerLink
Log in

Initial clinical experience with a selective A2A receptor agonist, regadenoson, in a patient with end-stage renal disease on hemodialysis

  • Nuclear Cardiology Bullet
  • Published:
Journal of Nuclear Cardiology Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2

References

  1. Bokhari S, Ficaro EP, McCallister BD Jr. Adenosine stress protocols for myocardial perfusion imaging. J Nucl Cardiol 2007;14:415-6.

    Article  PubMed  Google Scholar 

  2. Lexiscan prescribing information handbook, Lexiscan (regadenoson) prescribing package insert. Deerfield, IL: Astellas Pharma; 2008.

  3. Cerqueira MC, Nguyen P, et al. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging: Integrated ADVANCE-MPI trial results. JACC Cardiovasc Imaging 2008;1:307-16.

    Article  PubMed  Google Scholar 

  4. Gordi T, Blackburn B, Lieu H. Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function. J Clin Pharmacol 2007;47:825-33.

    Article  PubMed  CAS  Google Scholar 

  5. Adenosine prescribing information handbook, Adenosine (adenoscan) prescribing package insert. Deerfield, IL: Astellas Pharma; 2005.

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, North Shore University Hospital, Manhasset, USA

    Saaron Laighold & Regina Druz

Authors
  1. Saaron Laighold
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Regina Druz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Regina Druz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Laighold, S., Druz, R. Initial clinical experience with a selective A2A receptor agonist, regadenoson, in a patient with end-stage renal disease on hemodialysis. J. Nucl. Cardiol. 16, 478–480 (2009). https://doi.org/10.1007/s12350-008-9043-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12350-008-9043-z

Keywords

Search

Navigation